Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Sanofi : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi Therapeutic

share with twitter share with LinkedIn share with facebook
share via e-mail
09/20/2017 | 02:57pm CET
   By Sonia Amaral Rohter 

Sanofi SA (>> Sanofi) and Alnylam Pharmaceuticals Inc. (>> Alnylam Pharmaceuticals, Inc.) reported Wednesday that Patisiran met all primary and secondary endpoints in a Phase III trial of its use against a rare, inherited disorder.

The trial looked at the use of Patisiran in patients with hereditary transthyretin-mediated amyloidosis, a progressively debilitating disease in which a gene mutation causes the production of a type of abnormal protein that accumulates in body organs and tissues, damaging them. Patisiran is designed to target and silence the mechanism that leads to production of this protein.

Patisiran is part of a class of medicines called RNA interference, or RNAi, therapeutics that aim to inhibit the expression of certain genes in order to treat or prevent disease.

Alnylam Chief Executive John Maraganore said: "We are very proud to report the first-ever positive Phase III results for an RNAi therapeutic, marking the potential arrival of an entirely new class of medicines."

Alnylam said it would file a new drug application with the U.S. Food and Drug Administration in late 2017. Should the company receive regulatory approval, Alnylam will commercialize Patisiran in the U.S., Canada and Western Europe, while Sanofi Genzyme will commercialize the product in the rest of the world.

The full results of the trial will be presented on November 2.

Write to Sonia Amaral Rohter at [email protected]

Stocks mentioned in the article : Sanofi, Alnylam Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
12:55a SANOFI : No one to blame for dengue vaccine mess Duterte
12/13 France's Sanofi pins hopes on new drugs after setbacks
12/13 SANOFI : Banner stories of Manila's leading newspapers, Tuesday, Dec. 12, 2017
12/13 SANOFI : FDA Approves Sanofi's Admelog
12/13 SANOFI : CEO says M&A targets in oncology are 'very expensive'
12/13 MIT's LEAPS pilot aims to integrate data generation
12/13 SANOFI : US clears Sanofis follow-on insulin Admelog
12/13DJSANOFI : to Begin at Least 10 Phase 3 Studies Over Next 12 Months
12/13 SANOFI : Sanofi presents R&D strategy and innovative pipeline
More news
News from SeekingAlpha
12/13 Regeneron updates investors on collaboration programs with Sanofi
12/13 Sanofi expects to file nine regulatory submissions over next 18 months
12/11 Buy Celgene And Regeneron On The Dips As Insiders Are Buying
12/11 FDA approves Sanofi's rapid-acting insulin analog Admelog; shares up 1%
12/08 YOUR DAILY PHARMA SCOOP : Geron Update, Acorda Resubmits NDA, Sage Rallies
Financials (€)
Sales 2017 35 791 M
EBIT 2017 9 201 M
Net income 2017 8 158 M
Debt 2017 4 979 M
Yield 2017 4,03%
P/E ratio 2017 11,75
P/E ratio 2018 16,29
EV / Sales 2017 2,79x
EV / Sales 2018 2,74x
Capitalization 94 773 M
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 30
Average target price 84,2 €
Spread / Average Target 12%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-4.32%109 438
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.01%218 773
PFIZER10.04%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659